Multiple System Atrophy Pipeline Insight

DelveInsight’s, “Multiple System Atrophy Pipeline Insight, 2026” report provides comprehensive insights about 22+ companies and 24+ pipeline drugs in Multiple System Atrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Multiple System Atrophy Understanding

Multiple System Atrophy Overview

Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder that affects both the autonomic nervous system (which controls involuntary functions such as blood pressure, bladder function, and digestion) and the central nervous system responsible for movement and balance. MSA is classified as an atypical parkinsonian disorder and typically begins in adults aged 50–60 years. Two major subtypes are recognized: MSA-P (parkinsonian type) and MSA-C (cerebellar type). Symptoms usually worsen progressively over time.

The exact cause of MSA remains unknown. Current evidence suggests that the disease likely results from a combination of genetic susceptibility and environmental factors. Researchers have identified abnormal accumulation of the protein alpha-synuclein within glial cells of the brain as a key pathological feature. Variants in genes such as SNCA and COQ2 are being investigated as potential risk factors, although MSA is generally not considered a hereditary disease.

The pathophysiology of MSA is characterized by widespread neurodegeneration and the accumulation of misfolded alpha-synuclein protein within glial cells, forming structures known as glial cytoplasmic inclusions. These inclusions contribute to neuronal dysfunction and cell death in several regions of the central nervous system, including the basal ganglia, cerebellum, brainstem, and autonomic control centers. Degeneration of the basal ganglia leads to parkinsonian symptoms such as rigidity, bradykinesia, and postural instability, while cerebellar involvement results in impaired coordination, gait disturbances, and ataxia. Damage to autonomic pathways causes orthostatic hypotension, urinary dysfunction, bowel disturbances, sexual dysfunction, and abnormalities in sweating and temperature regulation. The progressive loss of neuronal function across multiple systems ultimately results in severe disability and reduced life expectancy.

The diagnosis of Multiple System Atrophy is primarily clinical and is based on a comprehensive evaluation of symptoms, neurological findings, and supportive diagnostic testing. Because there is no definitive laboratory test to confirm MSA during life, physicians rely on characteristic features such as autonomic failure, parkinsonism that responds poorly to levodopa, and cerebellar dysfunction. Diagnostic investigations may include magnetic resonance imaging (MRI) of the brain, autonomic function testing, tilt-table testing to assess orthostatic hypotension, urodynamic studies to evaluate bladder dysfunction, sleep studies for sleep-related breathing disorders, and additional neurological assessments. MRI may reveal characteristic abnormalities, including cerebellar and brainstem atrophy, which can support the diagnosis. Early diagnosis is often challenging because the symptoms can overlap with those of Parkinson’s disease and other neurodegenerative disorders.

There is currently no cure or disease-modifying therapy for Multiple System Atrophy, and treatment is focused on managing symptoms and improving quality of life. Orthostatic hypotension may be treated with medications such as midodrine, droxidopa, or fludrocortisone, along with lifestyle measures including increased fluid and salt intake when appropriate. Parkinsonian symptoms may show limited improvement with levodopa therapy, although the response is generally less robust than in Parkinson’s disease. Management of bladder dysfunction may involve medications, intermittent catheterization, or other supportive interventions. Speech therapy, physical therapy, and occupational therapy play important roles in maintaining communication, mobility, and independence. Patients with swallowing difficulties may require dietary modifications or feeding tube placement, while sleep-disordered breathing may be managed with continuous positive airway pressure (CPAP) or other respiratory support. Because MSA affects multiple body systems, treatment typically requires a multidisciplinary approach involving neurologists, rehabilitation specialists, and supportive care providers.

"Multiple System Atrophy Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Multiple System Atrophy pipeline landscape is provided which includes the disease overview and Multiple System Atrophy treatment guidelines. The assessment part of the report embraces, in depth Multiple System Atrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Multiple System Atrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Multiple System Atrophy Pipeline Report Highlights

The Multiple System Atrophy companies and academics are working to assess challenges and seek opportunities that could influence Multiple System Atrophy R&D. The therapies under development are focused on novel approaches to treat/improve Multiple System Atrophy.

Multiple System Atrophy Emerging Drugs Analysis

This segment of the Multiple System Atrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Multiple System Atrophy Emerging Drugs

Amlenetug: H. Lundbeck A/S

Amlenetug is an investigational human monoclonal antibody being developed for the treatment of Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative synucleinopathy. Amlenetug is designed to recognize and bind to all major forms of extracellular alpha-synuclein (α-synuclein), the pathogenic protein believed to drive disease progression in MSA. By binding extracellular α-synuclein, amlenetug is intended to prevent cellular uptake and inhibit the seeding and spread of α-synuclein aggregates between cells. The antibody also possesses an active Fc region that may enhance microglia-mediated immune clearance of α-synuclein/antibody complexes, thereby reducing pathological protein accumulation. For MSA, amlenetug has received several important regulatory designations, including Orphan Drug Designation (EMA), SAKIGAKE Designation (Japan MHLW), Orphan Drug Designation (US FDA), Orphan Drug Designation (Japan MHLW), and Fast Track Designation (US FDA). Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Multiple System Atrophy.

YA-101: Dasher Neuroscience Inc

YA-101 is an investigational New Chemical Entity (NCE) being developed for the treatment of Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative disorder. YA-101 was specifically designed for neurodegenerative diseases and has a dual mechanism of action centered on inhibiting neuroinflammation and enhancing neuroplasticity, with the goal of slowing disease progression and improving neurological function. Preclinical studies reportedly demonstrated improvements in motor-related behavioral impairments in animal models of MSA and ataxia, while a Phase I study in healthy volunteers in Australia established safety and tolerability. YA-101 has received multiple orphan-drug incentives, including U.S. FDA Orphan Drug Designation, Japan MHLW Orphan Drug Designation, and European Medicines Agency (EMA) Orphan Drug Designation for MSA. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Multiple System Atrophy.

hOMSC300: CytoraStem

hOMSC300 is an investigational allogeneic stem cell therapy for the treatment of Multiple System Atrophy (MSA). The product is based on human Oral Mucosa Stem Cells (hOMSCs), a proprietary stem-cell population derived from oral mucosal tissue. hOMSC300 is administered intrathecally and is intended to act as a disease-modifying therapy by providing neuroprotection, reducing neuroinflammation, and supporting neuronal survival and regeneration. Preclinical MSA models demonstrated that hOMSC300 exerted neuroprotective effects on dopaminergic neurons and dampened neuroinflammatory processes, which are believed to contribute to disease progression in MSA. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Multiple System Atrophy.

Further product details are provided in the report……..

Multiple System Atrophy Drug Therapeutic Assessment

This segment of the report provides insights about the different Multiple System Atrophy drugs segregated based on following parameters that define the scope of the report, such as:

Major Multiple System Atrophy Players in Multiple System Atrophy

There are approx. 22+ key companies which are developing the therapies Multiple System Atrophy. The companies which have their Multiple System Atrophy drug candidates in the most advanced stage, i.e. Phase III include, H. Lundbeck A/S, and others.

Multiple System Atrophy Clinical Trial Phases

DelveInsight’s report covers around 24+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Multiple System Atrophy Drug Route of Administration

Multiple System Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Multiple System Atrophy Product Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Multiple System Atrophy Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Multiple System Atrophy Clinical Trial Activities

The Multiple System Atrophy pipeline report provides insights into different Multiple System Atrophy clinical trials within phase II, I, preclinical and discovery stage. It also analyses Multiple System Atrophy therapeutic drugs key players involved in developing key drugs.

Multiple System Atrophy Pipeline Development Activities

The Multiple System Atrophy clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Multiple System Atrophy drugs.

Multiple System Atrophy Pipeline Report Insights

• Multiple System Atrophy Pipeline Analysis
• Multiple System Atrophy  Therapeutic Assessment
• Multiple System Atrophy  Unmet Needs
• Impact of Multiple System Atrophy Drugs

Multiple System Atrophy Pipeline Report Assessment

• Multiple System Atrophy Pipeline Product Profiles
• Multiple System Atrophy Therapeutic Assessment
• Multiple System Atrophy Pipeline Assessment
• Multiple System Atrophy Inactive drugs assessment
• Multiple System Atrophy Market Unmet Needs

Key Questions Answered In The Multiple System Atrophy Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Multiple System Atrophy drugs?
• How many Multiple System Atrophy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Multiple System Atrophy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Multiple System Atrophy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Multiple System Atrophy and their status?
• What are the key designations that have been granted to the emerging drugs?

Multiple System Atrophy Key Players

• H. Lundbeck A/S
• Teva Pharmaceutical Industries Ltd.
• Alterity Therapeutics
• Dasher Neuroscience Inc.
• Ionis Pharmaceuticals, Inc.
• Ono Pharmaceutical Co., Ltd.
• Biocells Medical
• Brain Neurotherapy Bio, Inc.
• Synusight Biotech (Shanghai) Co., Ltd.
• CytoraStem

Multiple System Atrophy Key Products

• Amlenetug
• TEV-56286
• ATH434
• YA-101
• ION464
• ONO-2808
• MSCs
• AAV2-GDNF gene therapy
• SST001
• hOMSC300